Isidoro Caraballo RodrÃ-guez

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8093639/publications.pdf

Version: 2024-02-01

76 papers	1,599 citations	279798 23 h-index	377865 34 g-index
79 all docs	79 docs citations	79 times ranked	1046 citing authors

#	Article	IF	Citations
1	Percolation theory: application to the study of the release behaviour from inert matrix systems. International Journal of Pharmaceutics, 1993, 96, 175-181.	5.2	75
2	Study of the critical points of HPMC hydrophilic matrices for controlled drug delivery. International Journal of Pharmaceutics, 2006, 311, 75-81.	5.2	69
3	Relationship between drug percolation threshold and particle size in matrix tablets. Pharmaceutical Research, 1996, 13, 387-390.	3.5	62
4	Printfills: 3D printed systems combining fused deposition modeling and injection volume filling. Application to colon-specific drug delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 134, 138-143.	4.3	56
5	The role of the drug/excipient particle size ratio in the percolation model for tablets. Pharmaceutical Research, 1998, 15, 216-220.	3.5	54
6	Factors affecting drug release from hydroxypropyl methylcellulose matrix systems in the light of classical and percolation theories. Expert Opinion on Drug Delivery, 2010, 7, 1291-1301.	5.0	51
7	Estimation of the percolation thresholds in acyclovir hydrophilic matrix tablets. European Journal of Pharmaceutics and Biopharmaceutics, 2006, 64, 336-342.	4.3	49
8	3D Printed Drug Delivery Systems Based on Natural Products. Pharmaceutics, 2020, 12, 620.	4.5	47
9	Investigation of the Influence of Particle Size on the Excipient Percolation Thresholds of HPMC Hydrophilic Matrix Tablets. Journal of Pharmaceutical Sciences, 2007, 96, 2746-2756.	3.3	45
10	A new biodegradable polythiourethane as controlled release matrix polymer. International Journal of Pharmaceutics, 2015, 480, 63-72.	5.2	41
11	Application of percolation theory in the study of an extended release Verapamil hydrochloride formulation. International Journal of Pharmaceutics, 2008, 361, 112-117.	5.2	38
12	Comparison of different mathematical models for the tensile strengthâ€“relative density profiles of binary tablets. European Journal of Pharmaceutical Sciences, 2004, 22, 19-23.	4.0	37
13	Study of the properties of the new biodegradable polyurethane PU (TEG-HMDI) as matrix forming excipient for controlled drug delivery. Drug Development and Industrial Pharmacy, 2013, 39, 1758-1764.	2.0	36
14	Synthesis and characterization of some new homo- and co-poly(vinylsaccharides). Some preliminary studies as drug delivery. Polymer, 2000, 41, 821-826.	3.8	35
15	Percolation thresholds in ultrasound compacted tablets. Journal of Controlled Release, 2000, 69, 345-355.	9.9	35
16	Design of controlled release inert matrices of naltrexone hydrochloride based on percolation concepts. International Journal of Pharmaceutics, 1999, 181, 23-30.	5.2	32
17	Study of critical points of drugs with different solubilities in hydrophilic matrices. International Journal of Pharmaceutics, 2010, 383, 138-146.	5.2	31
18	Communications Simultaneous Hplc Determination of some Drugs Commonly Used in Cold Medications: Dextromethorphan, Dephenhydramine, Phenylephrine, Phenylpropanolamine and Pseudoephedrine. Drug Development and Industrial Pharmacy, 1995, 21, 605-613.	2.0	29

#	Article	IF	Citations
19	Statistical Optimization of a Sustained-Release Matrix Tablet of Lobenzarit Disodium. Drug Development and Industrial Pharmacy, 2000, 26, 1303-1307.	2.0	28
20	Estimation of the percolation thresholds in dextromethorphan hydrobromide matrices. European Journal of Pharmaceutical Sciences, 2001, 12, 453-459.	4.0	28
21	Study of the critical points and the role of the pores and viscosity in carbamazepine hydrophilic matrix tablets. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 80, 136-142.	4.3	28
22	Reduction-sensitive functionalized copolyurethanes for biomedical applications. Polymer Chemistry, 2014, 5, 2370.	3.9	28
23	Study of percolation thresholds in ternary tablets. International Journal of Pharmaceutics, 1996, 139, 177-186.	5.2	26
24	First study of the evolution of the SeDeM expert system parameters based on percolation theory: Monitoring of their critical behavior. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 109, 158-164.	4.3	24
25	Physical characterization of carteolol: EudragitÂ® L binding interaction. International Journal of Pharmaceutics, 1995, 114, 13-21.	5.2	23
26	Study of the Critical Points in Lobenzarit Disodium Hydrophilic Matrices for Controlled Drug Delivery. Chemical and Pharmaceutical Bulletin, 2006, 54, 598-602.	1.3	23
27	Study of the release mechanism of carteolol inert matrix tablets on the basis of percolation theory. International Journal of Pharmaceutics, 1994, 109, 229-236.	5.2	22
28	Influence of diluents and manufacturing method on the in vitro dissolution of carteolol hydrochloride matrix tablets. International Journal of Pharmaceutics, 1995, 118, 151-160.	5.2	22
29	Study of morphine hydrochloride percolation threshold in EudragitÂ® RSâ€“PM matrices. International Journal of Pharmaceutics, 1998, 170, 169-177.	5.2	21
30	The influence of polymer content on early gel-layer formation in HPMC matrices: The use of CLSM visualisation to identify the percolation threshold. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 94, 485-492.	4.3	21
31	Achieving High Excipient Efficiency with Elastic Thermoplastic Polyurethane by Ultrasound Assisted Direct Compression. Pharmaceutics, 2019, 11, 157.	4.5	21
32	Evaluation of EudragitÂ® RS-PO and EthocelÂ® 100 Matrices for the Controlled Release of Lobenzarit Disodium. Drug Development and Industrial Pharmacy, 1999, 25, 229-233.	2.0	20
33	Study of the critical points of experimental HPMCâ€“NaCMC hydrophilic matrices. International Journal of Pharmaceutics, 2010, 386, 52-60.	5.2	20
34	Release behaviour of clozapine matrix pellets based on percolation theory. International Journal of Pharmaceutics, 2011, 404, 133-141.	5.2	19
35	Towards a rational basis for selection of excipients: Excipient Efficiency for controlled release. International Journal of Pharmaceutics, 2015, 494, 288-295.	5.2	19
36	3D printed systems for colon-specific delivery of camptothecin-loaded chitosan micelles. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 167, 48-56.	4.3	19

#	Article	IF	Citations
37	Polymer Percolation Threshold in HPMC Extended Release Formulation of Carbamazepine and Verapamil HCl. AAPS PharmSciTech, 2010, 11, 558-562.	3.3	18
38	Development and characterization of new functionalized polyurethanes for sustained and site-specific drug release in the gastrointestinal tract. European Journal of Pharmaceutical Sciences, 2017, 100, 285-295.	4.0	18
39	Thermoplastic polyurethane as matrix forming excipient using direct and ultrasound-assisted compression. European Journal of Pharmaceutical Sciences, 2019, 136, 104949.	4.0	18
40	Zero-order release periods in inert matrices. Influence of the distance to the percolation threshold. Pharmaceutica Acta Helvetiae, 1996, 71, 335-339.	1.2	17
41	Critical points in the formulation of pharmaceutical swellable controlled release dosage formsâ€"Influence of particle size. Particuology, 2009, 7, 421-425.	3.6	17
42	Morphine Polymeric Coprecipitates for Controlled Release: Elaboration and Characterization. Drug Development and Industrial Pharmacy, 1994, 20, 2409-2424.	2.0	16
43	Assessment of the Extrusion Process and Printability of Suspension-Type Drug-Loaded AffinisolTM Filaments for 3D Printing. Pharmaceutics, 2022, 14, 871.	4.5	16
44	Estimation of the percolation thresholds in ternary lobenzarit disodiumâ€"dextranâ€"HPMC hydrophilic matrices tablets: Effects of initial porosity. European Journal of Pharmaceutical Sciences, 2009, 38, 312-319.	4.0	15
45	Influence of two different types of excipient on drug percolation threshold. International Journal of Pharmaceutics, 1998, 174, 63-69.	5.2	14
46	Estimation of the percolation thresholds in lobenzarit disodium native dextran matrix tablets. AAPS PharmSciTech, 2007, 8, 281-288.	3.3	13
47	Critical points in ethylcellulose matrices: Influence of the polymer, drug and filler properties. Acta Pharmaceutica, 2013, 63, 115-129.	2.0	13
48	A Rapid HPLC Method for the Quantification of Tyrothricin, Menthol, and Benzocaine in Pharmaceutical Formulations. Journal of Pharmaceutical Sciences, 1994, 83, 1147-1149.	3.3	12
49	Design and evaluation of a new central core matrix tablet. International Journal of Pharmaceutics, 1997, 146, 175-180.	5.2	12
50	Study of thimerosal degradation mechanism. International Journal of Pharmaceutics, 1993, 89, 213-221.	5.2	11
51	Effect of drug particle size in ultrasound compacted tablets. International Journal of Pharmaceutics, 2006, 310, 168-174.	5.2	11
52	Early stages of drug crystallization from amorphous solid dispersion via fractal analysis based on chemical imaging. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 133, 122-130.	4.3	11
53	Application of Percolation Theory to Characterize the Release Behavior of Carteolol Matrix Systems. Drug Development and Industrial Pharmacy, 1997, 23, 1-8.	2.0	10
54	Validation study of the conductometrical analysis. Application to the drug release studies from controlled release systems. Journal of Pharmaceutical and Biomedical Analysis, 1998, 18, 281-285.	2.8	10

#	Article	IF	Citations
55	Preclinical study of a controlled release oral morphine system in rats. International Journal of Pharmaceutics, 1996, 139, 237-241.	5.2	9
56	Stability Study of Flutamide in Solid State and in Aqueous Solution. Drug Development and Industrial Pharmacy, 2002, 28, 413-422.	2.0	9
57	A New Wet Conductivimetric Method to Estimate the Drug Percolation Threshold. Pharmaceutical Research, 2004, 21, 875-881.	3.5	9
58	Formulation Factors Affecting Thimerosal Stability. Drug Development and Industrial Pharmacy, 1993, 19, 1673-1691.	2.0	8
59	Study of a complexation process between naltrexone and EudragitÂ® L as an oral controlled release system. International Journal of Pharmaceutics, 1997, 148, 219-230.	5.2	8
60	Design space and critical points in solid dosage forms. Journal of Drug Delivery Science and Technology, 2017, 42, 134-143.	3.0	8
61	Electron microscopy/energy dispersive X-ray spectroscopy of drug distribution in solid dispersions and interpretation by multifractal geometry. Journal of Pharmaceutical and Biomedical Analysis, 2018, 150, 241-247.	2.8	8
62	Application of ultrasound-assisted compression in pharmaceutical technology. Design and optimization of oral sustained-release dosageÂforms. Journal of Drug Delivery Science and Technology, 2017, 42, 119-125.	3.0	8
63	A new deferiprone controlled release system obtained by ultrasound-assisted compression. Pharmaceutical Development and Technology, 2014, 19, 728-734.	2.4	6
64	Application of a New Mathematical Method for the Estimation of the Mean Surface Area to Calculate the Percolation Threshold of Lobenzarit Dissodium Salt in Controlled Release Matrices. Chemical and Pharmaceutical Bulletin, 2004, 52, 797-801.	1.3	5
65	Benefits of Fractal Approaches in Solid Dosage Form Development. Pharmaceutical Research, 2019, 36, 156.	3.5	5
66	Critical points for predicting 3D printable filaments behaviour. Journal of Drug Delivery Science and Technology, 2021, 66, 102933.	3.0	5
67	Study of the critical points in combined matrix tablets containing both inert and swelling excipients. Journal of Drug Delivery Science and Technology, 2019, 52, 885-894.	3.0	4
68	Comparison of the performance of two grades of metformin hydrochloride elaboration by means of the SeDeM system, compressibility, compactability, and process capability indices. Drug Development and Industrial Pharmacy, 2021, 47, 484-497.	2.0	4
69	Influence of the pH Value of the Dissolution Medium on the Release Profiles of a Morphine Polymeric Complex. Drug Development and Industrial Pharmacy, 1997, 23, 553-559.	2.0	3
70	Preclinical Study of an Oral Controlled Release Naltrexone Complex in Mice. Journal of Pharmacy and Pharmacology, 2010, 52, 659-663.	2.4	3
71	Collaboration between HPMC and NaCMC in order to Reach the Polymer Critical Point in Theophylline Hydrophilic Matrices. Scientific World Journal, The, 2012, 2012, 1-8.	2.1	3
72	Novel Polyurethane Matrix Systems Reveal a Particular Sustained Release Behavior Studied by Imaging and Computational Modeling. AAPS PharmSciTech, 2017, 18, 1544-1553.	3.3	2

#	Article	IF	Citations
73	A Biodegradable Copolyester, Poly(butylene succinate-co-Îµ-caprolactone), as a High Efficiency Matrix Former for Controlled Release of Drugs. Pharmaceutics, 2021, 13, 1057.	4.5	2
74	Influence of the Disintegrant on the Drug Percolation Threshold in Tablets. Drug Development and Industrial Pharmacy, 1997, 23, 665-669.	2.0	0
75	Tablet Design. , 0, , 977-1051.		0
76	Critical Points in Biopolymeric-Controlled Release Matrix Systems. Advances in Material Research and Technology, 2020, , 31-55.	0.6	0